Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Cancer Diagnostics Market Size, Trends and Industry Outlook by Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer and others), End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030


ID: MRFR/MED/1430-HCR | 90 Pages | Author: Rahul Gotadki| April 2024

Cancer Diagnostics Market Segmentation


Cancer Diagnostics Type Outlook (USD Billion, 2018-2030)




  • Imaging Testing




  • Biomarkers Testing




  • In Vitro Diagnostic Testing




  • Biopsy and Others




Cancer Diagnostics Application Outlook (USD Billion, 2018-2030)




  • Lung Cancer




  • Breast Cancer




  • Colorectal Cancer




  • Melanoma Cancer




  • Prostate Cancer




  • Liver Cancer




  • Others




Cancer Diagnostics End-User Outlook (USD Billion, 2018-2030)




  • Diagnostic Centers




  • Hospitals and Clinics




  • Research Institutes




  • Others




Cancer Diagnostics Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • North America Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • North America Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • US Outlook (USD Billion, 2018-2030)




    • US Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • US Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • US Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Canada Outlook (USD Billion, 2018-2030)




    • Canada Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and Others






    • Canada Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Canada Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Europe Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Europe Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Germany Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • others






    • Germany Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • France Outlook (USD Billion, 2018-2030)




    • France Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • France Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • France Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • UK Outlook (USD Billion, 2018-2030)




    • UK Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • UK Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • UK Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Italy Outlook (USD Billion, 2018-2030)




    • Italy Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Italy Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Italy Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Spain Outlook (USD Billion, 2018-2030)




    • Spain Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Spain Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Spain Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Rest Of Europe Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Rest Of Europe Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Asia-Pacific Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Asia-Pacific Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • China Outlook (USD Billion, 2018-2030)




    • China Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • China Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • China Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Japan Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Japan Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • India Outlook (USD Billion, 2018-2030)




    • India Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • India Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • India Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Australia Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Australia Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Rest of Asia-Pacific Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Rest of Asia-Pacific Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Rest of the World Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • others






    • Rest of the World Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Middle East Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • others






    • Middle East Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Africa Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Africa Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Cancer Diagnostics by Type




      • Imaging Testing




      • Biomarkers Testing




      • In Vitro Diagnostic Testing




      • Biopsy and others






    • Latin America Cancer Diagnostics by Application




      • Lung Cancer




      • Breast Cancer




      • Colorectal Cancer




      • Melanoma Cancer




      • Prostate Cancer




      • Liver Cancer




      • Others






    • Latin America Cancer Diagnostics by End-User




      • Diagnostic Centers




      • Hospitals and Clinics




      • Research Institutes




      • Others







Research Methodology on Cancer Diagnostics Market


Cancer Diagnostics Market is a dynamic and ever-changing sector within the global healthcare economy, driven by advances in genomic technologies and diagnostics, as well as the adoption of new therapies and treatments. This report provides an in-depth review of the market trends, drivers and challenges, and potential opportunities. The research is based on a variety of sources including comprehensive surveys, interviews, and market observation.


Objective


This research aims to understand the recent trends in the cancer diagnostics market, identify potential opportunities, and gain insights into the key challenges and drivers of growth.


Research Questions


The research questions that this report aims to answer include:




  • What are the key trends in the cancer diagnostics market?




  • What challenges are facing the market today, and what opportunities are available?




  • What are the key drivers and forces of growth in this market?




  • How are different stakeholders affected by the changes in this market?




Research Approach


The research approach used for this report is a combination of qualitative and quantitative methods.


Quantitative Research


In order to determine the current size and value of the cancer diagnostics market, data from a variety of sources is reviewed and analyzed. This includes annual financial reports from major players in the market and publicly available data from market intelligence firms. The data collected is used to create estimates of market size and growth rates.


Qualitative Research


In order to understand the key drivers and challenges in the cancer diagnostics market, a series of interviews are conducted with stakeholders across the industry. This includes executives at major players in the market, investors, researchers, and other individuals with experience and expertise in the market. The interviews are semi-structured, with open-ended questions designed to gain insight into the perspectives of the individual.


Data Collection


Data is collected through a variety of sources, including surveys, interviews, and publicly available data. The data is collected from a variety of sources, including annual financial reports from major players in the market, market intelligence firms, and interviews with stakeholders across the industry.


Analysis


The collected data is analyzed using both qualitative and quantitative methods. Qualitative data is analyzed to understand the key drivers and challenges in the market, and quantitative data is used to estimate the size and value of the market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porterโ€™s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D and Designing

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Review

Chapter 6. Global Cancer Diagnostics Market, by Type

6.1 Overview

6.2 Imaging Testing

6.2.1 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.2 Computed Tomography (CT)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.3 Positron Emission Tomography (PET)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.3.1 Standalone Positron Emission Tomography

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.3.2 Hybrid Positron Emission Tomography

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.4 Mammography

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6. 2.5 Ultrasound

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.3 Biomarkers Testing

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.3.1 Protein Biomarker

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.2 Genetic Biomarker

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.3 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4 In Vitro Diagnostic Testing

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.1 Polymerase Chain Reaction (PCR)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.2 In Situ Hybridization (ISH)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.3 Immunohistochemistry Testing (IHC)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.4 Next-Generation Sequencing Testing (NGS)

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.5 Microarrays

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.6 Flow Cytometry

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.5 Molecular Diagnostics

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4.6 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.5 Biopsy

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.5.1 Needle Biopsy

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.5.2 Bone Marrow Biopsy

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.6 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

Chapter 7. Global Cancer Diagnostics Market, by Application

7.1 Overview

7.2 Lung Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.3 Breast Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.4 Colorectal Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.5 Melanoma Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.6 Prostate Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.7 Liver Cancer

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

7.8 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

Chapter 8. Global Cancer Diagnostics Market, by End User

8.1 Overview

82 Diagnostic Center

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

8.3 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

8.4 Research Institutes

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

8.5 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

Chapter 9. Global Cancer Diagnostics Market, by Region

9.1 Overview

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10 Company Landscape

10.1 Overview

10.2 Competitive Analysis

Chapter 11. Company Profile

11.1 Exact Sciences Corporation

11.1.1 Company Overview

11.1.2 Products/Services Offered

11.1.3 Financial Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategies

11.2 Arquer Diagnostics Ltd

11.2.1 Company Overview

11.2.2 Products/Services Offered

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 BioMark Diagnostics Inc.

11.3.1 Company Overview

11.3.2 Products/Services Offered

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.3.6 Key Strategies

11.4 Biotheranostics

11.4.1 Company Overview

11.4.2 Products/Services Offered

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.4.6 Key Strategies

11.5 Cancer Diagnostics, Inc.

11.5.1 Company Overview

11.5.2 Products/Services Offered

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

11.6 Agilent Technologies, Inc.

11.6.1 Company Overview

11.6.2 Products/Services Offered

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Thermo Fisher Scientific, Inc.

11.7.1 Overview

11.7.2 Products/Services Offered

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 Illumina, Inc.

11.8.1 Overview

11.8.2 Products/Services Offered

11.8.3 Financial Overview

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 Becton, Dickinson and Company

11.9.1 Overview

11.9.2 Products/Services Offered

11.9.3 Financial Overview

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 GE Healthcare

11.10.1 Overview

11.10.2 Products/Services Offered

11.10.3 Financial Overview

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 QIAGEN N.V.

11.11.1 Overview

11.11.2 Products/Services Offered

11.11.3 Financial Overview

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.6 Key Strategies

11.12 Abbott Laboratories, Inc.

11.12.1 Overview

11.12.2 Products/Services Offered

11.12.3 Financial Overview

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

11.13 Roche Diagnostics

11.13.1 Overview

11.13.2 Products/Services Offered

11.13.3 Financial Overview

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.13.6 Key Strategies

11.14 Siemens Healthcare

11.14.1 Overview

11.14.2 Products/Services Offered

11.14.3 Financial Overview

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.14.6 Key Strategies

11.15 Koninklijke Philips N.V.

11.15.1 Overview

11.15.2 Products/Services Offered

11.15.3 Financial Overview

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.15.6 Key Strategies

11.16 Others

Chapter 12 Appendix

12.1 References

12.2 Related Reports

LIST OF TABLES

Table 1 Global Cancer Diagnostics Market Synopsis, 2022-2030

Table 2 Global Cancer Diagnostics Market Estimates and Forecast, 2022-2030 (USD Million)

Table 3 Global Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 4 Global Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 5 Global Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 6 Global Cancer Diagnostics Market, by Region, 2022-2030 (USD Million)

Table 7 Americas: Cancer Diagnostics Market, by Region, 2020 and 2025

Table 8 Americas: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 9 Americas: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 10 Americas: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 11 North America: Cancer Diagnostics Market, by Country, 2022-2030 (USD Million)

Table 12 North America: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 13 North America: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 14 North America: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 15 US: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 16 US: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 17 US: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 18 Canada: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 19 Canada: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 20 Canada: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 21 Latin America: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 22 Latin America: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 23 Latin America: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 24 Europe: Cancer Diagnostics Market, by Region, 2022-2030 (USD Million)

Table 25 Europe: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 26 Europe: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 27 Europe: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 28 Western Europe: Cancer Diagnostics Market, by Country, 2022-2030 (USD Million)

Table 29 Western Europe: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 30 Western Europe: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 31 Western Europe: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 32 Eastern Europe: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 33 Eastern Europe: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 34 Eastern Europe: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 35 Asia-Pacific: Cancer Diagnostics Market, by Country, 2022-2030 (USD Million)

Table 36 Asia-Pacific: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 37 Asia-Pacific: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 38 Asia-Pacific: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

Table 39 Middle East & Africa: Cancer Diagnostics Market, by Region, 2022-2030 (USD Million)

Table 40 Middle East & Africa: Cancer Diagnostics Market, by Type, 2022-2030 (USD Million)

Table 41 Middle East & Africa: Cancer Diagnostics Market, by Application, 2022-2030 (USD Million)

Table 42 Middle East & Africa: Cancer Diagnostics Market, by End User, 2022-2030 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure of the Global Cancer Diagnostics Market

Figure 3 Market Dynamics of the Global Cancer Diagnostics Market

Figure 4 Global Cancer Diagnostics Market Share, by Type, 2020 (%)

Figure 5 Global Cancer Diagnostics Market Share, by Type, 2020 (USD Million)

Figure 6 Global Cancer Diagnostics Market Share, by Application, 2020 (%)

Figure 7 Global Cancer Diagnostics Market Share, by Application, 2020 (USD Million)

Figure 8 Global Cancer Diagnostics Market Share, by End User, 2020 (%)

Figure 9 Global Cancer Diagnostics Market Share, by End User, 2020 (USD Million)

Figure 10 Global Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 11 Americas: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 12 North America: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 13 Europe: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 14 Western Europe: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 15 Asia-Pacific: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 16 Middle East & Africa: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 17 Global Cancer Diagnostics Market: Company Share Analysis, 2020 (%)

Figure 18 Exact Sciences Corporation: Key Financials

Figure 19 Exact Sciences Corporation: Segmental Revenue

Figure 20 Exact Sciences Corporation: Regional Revenue

Figure 21 Arquer Diagnostics Ltd: Key Financials

Figure 22 Arquer Diagnostics Ltd: Segmental Revenue

Figure 23 Arquer Diagnostics Ltd: Regional Revenue

Figure 24 BioMark Diagnostics Inc.: Key Financials

Figure 25 BioMark Diagnostics Inc.: Segmental Revenue

Figure 26 BioMark Diagnostics Inc.: Regional Revenue

Figure 27 Biotheranostics: Key Financials

Figure 28 Biotheranostics: Segmental Revenue

Figure 29 Biotheranostics: Regional Revenue

Figure 30 Cancer Diagnostics, Inc.: Key Financials

Figure 31 Cancer Diagnostics, Inc.: Segmental Revenue

Figure 32 Cancer Diagnostics, Inc.: Regional Revenue

Figure 33 Agilent Technologies, Inc.: Key Financials

Figure 34 Agilent Technologies, Inc.: Segmental Revenue

Figure 35 Agilent Technologies, Inc.: Regional Revenue

Figure 36 Thermo Fisher Scientific, Inc.: Key Financials

Figure 37 Thermo Fisher Scientific, Inc.: Segmental Revenue

Figure 38 Thermo Fisher Scientific, Inc.: Regional Revenue

Figure 39 Illumina, Inc.: Key Financials

Figure 40 Illumina, Inc.: Segmental Revenue

Figure 41 Illumina, Inc.: Regional Revenue

Figure 42 Becton, Dickinson and Company: Key Financials

Figure 43 Becton, Dickinson and Company: Segmental Revenue

Figure 44 Becton, Dickinson and Company: Regional Revenue

Figure 45 GE Healthcare: Key Financials

Figure 46 GE Healthcare: Segmental Revenue

Figure 47 GE Healthcare: Regional Revenue

Figure 48 QIAGEN N.V.: Key Financials

Figure 49 QIAGEN N.V.: Segmental Revenue

Figure 50 QIAGEN N.V.: Regional Revenue

Figure 51 Abbott Laboratories, Inc.: Key Financials

Figure 52 Abbott Laboratories, Inc.: Segmental Revenue

Figure 53 Abbott Laboratories, Inc.: Regional Revenue

Figure 54 Roche Diagnostics: Key Financials

Figure 55 Roche Diagnostics: Segmental Revenue

Figure 56 Roche Diagnostics: Regional Revenue

Figure 57 Siemens Healthcare: Key Financials

Figure 58 Siemens Healthcare: Segmental Revenue

Figure 59 Siemens Healthcare: Regional Revenue

Figure 60 Koninklijke Philips N.V.: Key Financials

Figure 61 Koninklijke Philips N.V.: Segmental Revenue

Figure 62 Koninklijke Philips N.V.: Regional Revenue

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.